Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11904662 | 0.76 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL8191444 | 0.70 | ALDH1A1 (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL1077227 | 0.63 | CYP3A4 (0.35) | CYP3A4MAPTL3MBTL1 | |
| SCHEMBL18106821 | 0.62 | CYP3A4 (0.42) | ALDH1A1CYP3A4MAPTL3MBTL1 | |
| SCHEMBL24591674 | 0.61 | CYP3A4 (0.46) | ALDH1A1CYP3A4MAPTL3MBTL1 | |
| SCHEMBL8418363 | 0.61 | CYP3A4 (0.46) | ALDH1A1CYP3A4MAPTL3MBTL1 | |
| SCHEMBL30479506 | 0.60 | CYP3A4 (0.41) | ALDH1A1CYP3A4MAPTL3MBTL1 | |
| SCHEMBL7065991 | 0.59 | — | — | |
| SCHEMBL21227243 | 0.59 | ALDH1A1 (0.36) | ALDH1A1CYP3A4 | |
| SCHEMBL18106828 | 0.59 | CYP3A4 (0.39) | ALDH1A1CYP3A4MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4392140-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2011005786-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005765-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005793-A1 | CELL-BASED BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010011895-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | ALDH1A1 4491/4885CYP3A4 3652/4885MAPT 2662/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | ALDH1A1 2999/4885CYP3A4 4760/4885MAPT 4832/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | ALDH1A1 3662/4885CYP3A4 4043/4885MAPT 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.